Evidence map›Paper›PMID 40255203›Full record

ReviewThe international journal of neuropsychopharmacology2025

Moving toward precision and personalized treatment strategies in psychiatry.

Stefano Comai, Mirko Manchia, Marta Bosia, Alessandro Miola, Sara Poletti, Francesco Benedetti, Sofia Nasini, Raffaele Ferri, Dan Rujescu, Marion Leboyer and 3 more

Abstract readReview
In one paragraph

Review in The international journal of neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Trial
  2. Big data and psychiatry: advances, constraints and future directions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
    Article
  3. Review
  4. Article
  5. Polygenic risk meets early trauma: toward a neuropsychodevelopmental model of schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stefano ComaiDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.ORCID 0000-0002-5686-7194
Mirko ManchiaUnit of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Marta BosiaIRCSS San Raffaele Scientific Institute, Milan, Italy.
Alessandro MiolaDepartment of Neuroscience, University of Padova, Padua, Italy.
Sara PolettiIRCSS San Raffaele Scientific Institute, Milan, Italy.
Francesco BenedettiIRCSS San Raffaele Scientific Institute, Milan, Italy.
Sofia NasiniDepartment of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Raffaele FerriOasi Research Institute-IRCCS, Troina, Italy.ORCID 0000-0001-6937-3065
Dan RujescuDepartment of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria.
Marion LeboyerUniversité Paris-Est Créteil (UPEC), Translational Neuropsychiatry Laboratory (INSERM U955 IMRB), Département de Psychiatrie (DMU IMPACT, AP-HP, Hôpital Henri Mondor), Fondation FondaMental, ECNP Immuno-NeuroPsychiatry Network, 94010 Créteil, France.
Julio LicinioSUNY Upstate Medical University, Syracuse, NY, United States.
Bernhard T BauneDepartment of Psychiatry and Psychotherapy, University of Münster, Münster, Germany.
Alessandro SerrettiOasi Research Institute-IRCCS, Troina, Italy.ORCID 0000-0003-4363-3759

Funding

European Union's Horizon Europe 101057454
6 · The paper itself

Abstract

Precision psychiatry aims to improve routine clinical practice by integrating biological, clinical, and environmental data. Many studies have been performed in different areas of research on major depressive disorder, bipolar disorder, and schizophrenia. Neuroimaging and electroencephalography findings have identified potential circuit-level abnormalities predictive of treatment response. Protein biomarkers, including IL-2, S100B, and NfL, and the kynurenine pathway illustrate the role of immune and metabolic dysregulation. Circadian rhythm disturbances and the gut microbiome have also emerged as critical transdiagnostic contributors to psychiatric symptomatology and outcomes. Moreover, advances in genomic research and polygenic scores support the perspective of personalized risk stratification and medication selection. While challenges remain, such as data replication issues, prediction model accuracy, and scalability, the progress so far achieved underscores the potential of precision psychiatry in improving diagnostic accuracy and treatment effectiveness.

Indexed as

Mental DisordersPrecision MedicinePsychiatryBiomarkersHumansBiomarkersbiomarkersbipolar disordermajor depressionpersonalized medicineschizophrenia

Identifiers

PMID40255203
PMCPMC12084835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.